Vitamin D Deficiency Raises Aggressive PCa Risk
Severe vitamin D deficiency linked with higher grade and stage of prostate tumors.
Vitamin D levels appear to be associated with first prostate biopsy outcomes, according to research published in Clinical Cancer Research.
Adam B. Murphy, M.D., of Northwestern University in Chicago, and colleagues analyzed data from 667 men, aged 40 to 79 years, to assess the association between serum 25-hydroxyvitamin D (25[OH]D) levels and outcomes of first prostate biopsy.
The researchers found that, among European-American men, 25(OH)D less than 12 ng/mL was associated with Gleason score ≥4+4 (odds ratio [OR], 3.66; 95 percent confidence interval [CI], 1.41 to 9.50; P = 0.008) and more advanced tumor stage (stage ≥cT2b versus ≤cT2a; OR, 2.42; 95 percent CI, 1.14 to 5.10; P = 0.008).
Among African-American men, 25(OH)D less than 20 ng/mL was associated with increased risk of prostate cancer diagnosis on biopsy (OR, 2.43; 95 percent CI, 1.20 to 4.94; P = 0.01). Also, among African-American men, 25(OH)D less than 12 ng/mL was associated with Gleason score ≥4+4 (OR, 4.89; 95 percent CI, 1.59 to 15.07; P = 0.006) and more advanced tumor stage (stage ≥cT2b versus ≤cT2a; OR, 4.22; 95 percent CI, 1.52 to 11.74; P = 0.003).
"In both European-American and African-American men, severe deficiency was positively associated with higher Gleason grade and tumor stage," the authors write.
One author disclosed financial ties to the biomedical industry.